OBJECTIVE： To study the bioequivalence of Levodopa micro-capsule floating tablets in Beagle dogs after multi- dose administration. METHODS： 6 dogs were collected and divided into Levodopa micro-capsule floating tablets group and Compound levodopa preparation group （Benserazide tablet， reference preparation）. They were given levodopa 200 mg intragastrically， every 8 h， for consecutive 4 day. In two-period crossover test， HPLC method was established to determine the concentration of levodopa in dog. The pharmacokinetic parameter， bioequivalence and plasma concentration fluctuation of steady state were calculated. RESULTS： The main pharmacokinetic parameters of Levodopa micro-capsule floating tablets and reference preparation were as that cmax were （4.23±0.75） and （8.47±1.18） μg/ml； AUC0-∞ were （12.18±1.16） and （13.81±2.12） μg·h/ml； tmax were（1.83±0.26） and （0.67±0.13） h， respectively. 90％ confidence intervals for the geometric mean ratio of AUC0-∞ for test and reference preparation were 80.61％-97.90％， and that for cmax were 42.75％-57.63％， respectively. There was statistical significance in tmax between test and reference preparation. Degree of fluctuation of test and reference preparation at steady state were （283.914±43.217）％ and （506.489±78.965）％， and fluctuation coefficient were （177.463±7.873）％ and （187.405±1.650）％， respectively. The degree of fluctuation of test preparation was significantly less than that of reference preparation. CONCLUSIONS： Levodopa micro-capsule floating tablets show good sustained-release property， and are bioequivalent with reference preparation in absorption after multiple dose administration. It also has lesser fluctuation of blood concentration.